1228 Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours

Authors :: Cristina Noberasco
S. Boselli
Giovanni Citterio
T. De Pas
F. de Braud
Claudio Bordignon
M. Giovannini
Vanesa Gregorc
F. Caligaris Cappio
Antonio Lambiase
Source :: European Journal of Cancer Supplements. 7:129
Publication Year :: 2009
Publisher :: Elsevier BV, 2009.

Subjects :: Cancer Research
chemistry.chemical_compound
Oncology
NGR-hTNF
chemistry
Refractory
business.industry
Vascular-targeting agent
Medicine
Pharmacology
business
Phase i study

Full Text Access

Tools